Compugen Ltd. Stock
Price
Target price
€2.01
€2.01
7.980%
0.144
7.980%
€3.67
02.05.24 / Tradegate
WKN: 553001 / Symbol: CGEN / Name: Compugen / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Compugen Ltd. Stock
A very strong showing by Compugen Ltd. today, with an increase of €0.14 (7.980%) compared to yesterday's price.
Based on 2 Buy predictions and 2 Sell predictions the sentiment towards Compugen Ltd. is rather balanced.
With a target price of 3 € there is a positive potential of 49.63% for Compugen Ltd. compared to the current price of 2.01 €.
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 7.980% | 12.011% | -8.028% | 261.261% | 23.006% | - | - |
| Chromadex Corp | 1.810% | 8.696% | 4.790% | 180.000% | 161.194% | -51.724% | - |
| Organovo Holdings Inc. | 10.940% | 2.872% | 1.363% | -43.118% | -5.750% | -85.556% | -94.698% |
| Intellia Therapeutics Inc | 1.470% | 13.026% | -5.028% | -37.275% | -24.318% | -64.164% | 62.236% |
Comments
Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) had its price target raised by analysts at Stifel Nicolaus from $3.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
